Financing

Tracon Pharmaceuticals launches $58 million IPO bid

Posted on 06 January 2015

Tags: ,

TRACON Pharmaceuticals, which is developing antibodies to treat cancer, AMD and fibrotic diseases, filed with the SEC to raise up to $58 million in an initial public offering.

Searching for more deal information? Current Partnering offers the following options:

  • CP Reports | Browse titles | Over 200 report titles that focus upon different deal types from licensing, co-promotion to distribution, biomarkers to drug delivery, oncology to psychiatry, all of which provide you with an insight into the latest life science deal making trends
  • Current Agreements | Login | Find out more | Updated daily by our industry analysts, our fully searchable life sciences intelligence database allows you to find deals and alliances dating as far back as 2000 saving you valuable time on your deal making research activities

 

The San Diego, CA-based company, which was founded in 2004, plans to list on the NASDAQ under the symbol TCON.

TRACON Pharmaceuticals initially filed confidentially on August 8, 2014.

Wells Fargo Securities and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.

For further deal information visit Current Agreements (subscription required)

Related

Scorecard: Top partnering deals by value in 2014

View: Top pharmaceutical companies

View: Top biotech companies

Report:   Top 50 Big Pharma Partnering and M&A Deal Trends

Report:   Top 50 Big Biotech Partnering and M&A Deal Trends

Print Friendly, PDF & Email

Leave a Reply

 

cpbannerad300x150new1gif
rauconbadgejpg
e78banner300x150animgif
cpbannerad300x150new2gif
e79banner300x150gif
e78banner300x150animgif